全球滅活小兒麻痺病毒疫苗市場：現況分析與預測（2023-2030）

滅活小兒麻痺疫苗是預防小兒麻痺疾病的安全有效的疫苗。 小兒麻痺是由小兒麻痺病毒引起的高度傳染性疾病，它會感染人類的免疫系統。 該疫苗含有滅活或 "滅活" 的小兒麻痺病毒株。 IPV 不是活病毒疫苗，不會引起小兒麻痺或其他疾病。 IPV 由死病毒顆粒製成，已被削弱到無法複製或引起感染的程度。 因此，即使對於免疫系統較弱的人來說也是安全的。 疫苗被注射到體內，刺激免疫系統產生抗體並抵抗病毒。 疫苗通常透過注射到手臂中來注射，例如接受化療或服用免疫抑制劑的人。 政府和社區關於疫苗接種重要性的意識計劃的激增等因素正在推動市場的發展。 例如，2020年，全球根除小兒麻痺倡議（GPEI）啟動了對其根除小兒麻痺策略的審查，即《2022-2026年根除小兒麻痺策略》。 該策略為實現永久、永續的無脊灰病毒世界提供了路線圖。 其他因素，例如醫療框架的進步以及公共當局、機構和醫療服務領域敏感領域的投機不斷增加，正在推動預測期內的市場發展。 此外，對全球根除小兒麻痺的日益關注以及世界衛生組織（WHO）等組織推動的新的根除小兒麻痺措施的推出進一步支持了市場發展。 例如，2020 年，美國疾病管制與預防中心估計，全球83% 的1 歲以下嬰兒在常規兒童免疫接種過程中接受了三劑或以上Pol3 疫苗接種，其中80% 的嬰兒至少接受過一次完整疫苗接種(IPV1)。已接受至少兩次分劑量 (IPV1)。

由於需要根除的脊髓灰質炎病例不斷增加，製藥公司提供的有效疫苗數量不斷增加，全球滅活脊髓灰質炎病毒疫苗市場預計將穩定增長約5.1%。馬蘇。 例如，根據美國疾病管制與預防中心2022年8月的數據，滅活小兒麻痺疫苗（IPV）接種兩劑後對麻痺性小兒麻痺有效率超過90%，接種三劑後有效率達99%至100%。是正確的。 已經引入了許多新療法來治療這種致命的脊髓灰質炎病毒。 其他幾個因素，例如有前途的製藥公司的建立、更好的治療方法及其成本效益的引入以及政府舉措，正在推動滅活脊髓灰質炎病毒疫苗的全球市場穩步發展。 例如，Serum Institute是一家成立於印度的疫苗製造商，也是全球最大的疫苗製造商之一。 我們生產多種疫苗，包括 IPV 疫苗。 IPV又稱IPV-BB疫苗，以其優良的品質和性價比而聞名。 多年來，血清研究所經歷了國內和國際市場的顯著擴張。

依類型，市場分為人類二倍體細胞和猴腎細胞。 人類二倍體細胞部分在全球滅活小兒麻痺病毒疫苗市場中佔有最大份額。 該細分市場佔據市場主導地位，因為它是最有效、使用最廣泛的疫苗。 人類二倍體細胞 (HDC) 疫苗是使用人類二倍體 (HDP) 細胞培養物生產的。 在明確動物細胞不適合生產小兒麻痺病毒後，開始發展這種小兒麻痺疫苗細胞系。 此類疫苗已獲得授權並適用於世界各個地區。 例如，滅活（人類二倍體細胞）小兒麻痺疫苗Poliovax已獲得美國食品藥物管理局（FDA）的疫苗批准。 因此，由於上述原因，人類二倍體細胞細分市場將在2022年佔據重要的市場份額。

根據銷售管道，市場分為公共部門和私部門。 預計私營部門在預測期內將佔據很大的市場份額，因為私人健康保險涵蓋所有免疫接種，包括六個月以下嬰兒的免疫接種。 除此之外，脊髓灰質炎病例數量和工作量的不斷增加導致醫院患者數量增加，並推動了這一領域的成長。 經過不懈努力，全世界已成功減少小兒麻痺的傳播。 據世界衛生組織 (WHO) 稱，如果不採取這些措施，到 2023 年 10 月，目前行走的超過 2,000 萬人將陷入癱瘓。 光是 2020 年，在疫苗接種活動中系統性地施用維生素 A 就避免了 150 萬名兒童死亡。 非洲成為 2020 年第五個宣布消滅野生小兒麻痺的地區。 因此，在分銷管道中，私人類別預計在預測期內錄得較高的複合年增長率。

為了更了解滅活小兒麻痺疫苗的市場介紹，市場有北美（美國、加拿大等北美地區）、歐洲（德國、英國、法國、西班牙、義大利等歐洲地區）、亞洲太平洋地區（中國、日本、印度、亞太地區其他地區）和世界其他地區。 由於小兒麻痺病例持續發生、疫苗接種率飆升以及對開發有效療法的投資不斷增加，2022年全球滅活小兒麻痺病毒疫苗市場將由北美主導。 政府機構已啟動小兒麻痺宣傳計劃，為患者提供有效的治療。 例如，根據 Frontiers Media S.A. 2020 年 7 月發表的一篇文章，疫苗的開發、許可和推出是作為大規模系統免疫計劃的一部分，該計劃開始解決北美的健康差距。 因此，2022年北美將佔據很大的市場份額。

目錄

第一章市場介紹

• 市場定義
• 主要目標
• 利害關係人
• 限制

第二章研究方法或假設

• 調查過程
• 調查方法
• 受訪者簡介

第三章市場總結

第 4 章執行摘要

第五章 COVID-19 對全球滅活小兒麻痺病毒疫苗市場的影響

第六章全球滅活小兒麻痺病毒疫苗市場收入（2020-2030）

第 7 章按類型劃分的市場洞察

• 人類二倍體細胞
• 猴腎細胞

第 8 章依通路劃分的市場洞察

• 公開
• 私人

第 9 章按地區劃分的市場洞察

• 北美
  • 美國
  • 加拿大
  • 其他北美地區
• 歐洲
  • 德國
  • 英國
  • 法國
  • 義大利
  • 西班牙
  • 其他歐洲地區
• 亞太地區
  • 中國
  • 日本
  • 印度
  • 其他亞太地區
• 世界其他地區

第十章全球滅活小兒麻痺病毒疫苗市場動態

• 市場驅動因素
• 市場挑戰
• 影響分析

第 11 章滅活小兒麻痺病毒疫苗的全球市場機會

第十二章滅活小兒麻痺病毒疫苗的全球市場趨勢

第十三章需求方與供給方分析

• 需求方分析
• 供給面分析

第14章價值鏈分析

第15章競爭場景

• 競爭狀況
  • 波特五力分析

第十六章公司簡介

• Bharat Biotech.
• BIO-MED
• Serum Institute of India Pvt. Ltd.
• Kedrion
• GSK plc.
• Bilthoven Biologicals
• Merck & Co., Inc.
• Pfizer Inc.
• Cadila Pharmaceuticals
• Berna Biotech Pharma GmbH

第十七章免責聲明

The inactivated polio vaccine is a safe and effective vaccine to prevent polio disease. Polio is a highly contagious disease caused by poliovirus that infects the human immune system. It contains killed or "inactivated" poliovirus strains. IPV is not a live virus vaccine, so it cannot cause polio or any other illness. It is made from killed virus particles, which are then weakened to the point where they cannot replicate or cause infection. This makes it safe for people with weakened immune systems. The vaccine is injected into the body to stimulate the immune system to make antibodies to fight off the virus. The vaccine is usually given through an injection into the arm, such as those undergoing chemotherapy or taking immunosuppressive drugs, to receive the vaccine. Factors such as a surge in government and community awareness programs concerning the significance of vaccination are driving the market. For instance, in 2020, the Global Polio Eradication Initiative (GPEI) launched a review of the strategy polio eradication strategy 2022 - 2026 for polio eradication. The strategy provides a roadmap for achieving a lasting and sustainable world free of poliovirus. Other factors, including advancements in medical care framework, and expanded speculations from the public authority, public, and confidential areas in medical services divisions are driving the development of the market during the forecast period. Moreover, the rising spotlight on eliminating polio globally and the introduction of new polio-eradicating initiatives driven by associations like the World Health Organization (WHO) further reinforce market development. For instance, in 2020, the Centers for Disease Control and Prevention estimated global coverage with more than 3 doses of Pol3 for infants <1 year of age vaccinated during routine childhood immunizations with 83% of children receiving more than 1 full dose (IPV1) and 80% receiving more than 2 fractional doses (IPV1).

The Global Inactivated Poliovirus Vaccine Market is expected to grow at a steady rate of around 5.1% owing to the increase in effective vaccines offered by pharmaceutical companies due to the constant growth in polio cases which needs to be controlled. For instance, according to the Centers for Disease Control and Prevention in August 2022, two doses of inactivated polio vaccine (IPV) were 90% effective or more against paralytic polio; three doses were 99% to 100% effective. Many new therapies are being introduced to treat this deadly polio virus. Several other factors, such as the establishment of potential pharmaceutical companies, the introduction of better therapeutics and their cost-effectiveness, and government initiatives are also driving this market of global inactivated poliovirus vaccines at a steady rate. For instance, Serum Institute is a vaccine manufacturer established in India and is one of the largest vaccine manufacturers in the world. It manufactures a variety of vaccines, including the IPV vaccine. The IPV, also known as the IPV-BB vaccine, is renowned for its superior quality and cost-effectiveness. Over the years, Serum Institute has experienced significant market expansion, both domestically and internationally.

Based on type, the market is bifurcated into human diploid cells and monkey kidney cells. The human diploid cell segment held the maximum share in the global market of inactivated poliovirus vaccines 2022. This segment dominated the market because of the higher efficacy. These are the most widely used type of vaccine. Human diploid cell (HDC) vaccines are produced using human diploid (HDP) cell cultures. The development of this cell line for polio vaccines began when it became apparent that animal cells were unsuitable for producing polioviruses. Various regions of the world have licensed and adapted the usage of such vaccines. For instance, the Poliovirus vaccine Inactivated (human diploid cell) vaccine Poliovax has been granted a vaccine license in the U.S. by the Food and Drug Administration (FDA). Hence, for the above reasons, the human diploid cell segment held a significant market share in 2022.

Based on the distribution channel, the market is bifurcated into public and private. The private segment is expected to hold a significant share of the market in the forecast period owing to private health insurance providing coverage for all vaccinations, including vaccinations for infants under six months of age. Apart from this, the constant number of cases of polio and workload is boosting the hospital's patient load and impelling this segment's growth. With constant efforts, the world has seen success in controlling polio spread to a major extent. For instance, according to the World Health Organization (WHO), in October of 2023, over 20 million people walking today would otherwise be paralyzed. Vaccine-systematic vitamin A administration during immunization activities has prevented an estimated 1,500,000 childhood deaths in 2020 alone. Africa became the 5th region to be declared wild Polio-free in 2020. Hence, amongst distribution channels, the private category is expected to witness a higher CAGR during the forecast period.

For a better understanding of the market adoption of inactivated poliovirus vaccine, the market is analyzed based on its worldwide presence in countries such as North America (U.S., Canada, and Rest of North America), Europe (Germany, U.K., France, Spain, Italy, Rest of Europe), Asia-Pacific (China, Japan, India, Rest of Asia-Pacific), Rest of World. North America dominated the global inactivated poliovirus vaccine market in 2022 due to the constant polio cases, surge in vaccination rate, and rising investments in developing effective therapeutics. Government organizations are initiating polio awareness programs to provide efficient care to patients. For instance, according to an article published in Frontiers Media S.A. in July 2020, vaccines were developed, licensed, and introduced as part of large systematic immunization programs that began to address health disparities in North America. Thus, North America held a significant share of the market in the year 2022.

Some of the major players operating in the market include: Bharat Biotech.; BIO-MED; Serum Institute of India Pvt. Ltd.; Kedrion; GSK plc.; Bilthoven Biologicals; Merck & Co.; Inc.; Pfizer Inc.; Cadila Pharmaceuticals; Berna Biotech Pharma GmbH.

TABLE OF CONTENTS

1 MARKET INTRODUCTION

• 1.1. Market Definitions
• 1.2. Main Objective
• 1.3. Stakeholders
• 1.4. Limitation

2 RESEARCH METHODOLOGY OR ASSUMPTION

• 2.1. Research Process of the Global Inactivated Poliovirus Vaccine Market
• 2.2. Research Methodology of the Global Inactivated Poliovirus Vaccine Market
• 2.3. Respondent Profile

3 MARKET SYNOPSIS

4 EXECUTIVE SUMMARY

5 IMPACT OF COVID-19 ON THE GLOBAL INACTIVATED POLIOVIRUS VACCINE MARKET

6 GLOBAL INACTIVATED POLIOVIRUS VACCINE MARKET REVENUE (USD BN), 2020-2030F

7 MARKET INSIGHTS BY TYPE

• 7.1. Human Diploid Cell
• 7.2. Monkey Kidney Cell

8 MARKET INSIGHTS BY DISTRIBUTION CHANNEL

• 8.1. Public
• 8.2. Private

9 MARKET INSIGHTS BY REGION

• 9.1. North America
  • 9.1.1. U.S.
  • 9.1.2. Canada
  • 9.1.3. Rest of North America
• 9.2. Europe
  • 9.2.1. Germany
  • 9.2.2. U.K.
  • 9.2.3. France
  • 9.2.4. Italy
  • 9.2.5. Spain
  • 9.2.6. Rest of Europe
• 9.3. Asia-Pacific
  • 9.3.1. China
  • 9.3.2. Japan
  • 9.3.3. India
  • 9.3.4. Rest of Asia-Pacific
• 9.4. Rest of World

10 GLOBAL INACTIVATED POLIOVIRUS VACCINE MARKET DYNAMICS

• 10.1. Market Drivers
• 10.2. Market Challenges
• 10.3. Impact Analysis

11 GLOBAL INACTIVATED POLIOVIRUS VACCINE MARKET OPPORTUNITIES

12 GLOBAL INACTIVATED POLIOVIRUS VACCINE MARKET TRENDS

13 DEMAND AND SUPPLY-SIDE ANALYSIS

• 13.1. Demand Side Analysis
• 13.2. Supply Side Analysis

14 VALUE CHAIN ANALYSIS

15 COMPETITIVE SCENARIO

• 15.1. Competitive Landscape
  • 15.1.1. Porters Fiver Forces Analysis

16 COMPANY PROFILED

• 16.1. Bharat Biotech.
• 16.2. BIO-MED
• 16.3. Serum Institute of India Pvt. Ltd.
• 16.4. Kedrion
• 16.5. GSK plc.
• 16.6. Bilthoven Biologicals
• 16.7. Merck & Co., Inc.
• 16.8. Pfizer Inc.
• 16.9. Cadila Pharmaceuticals
• 16.10. Berna Biotech Pharma GmbH

17 DISCLAIMER